WHAT IS CLAIMED IS:

1. Use of fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a COVID-19 infection.

2. The use of claim 1, wherein the patient has or is expected to develop acute respiratory distress syndrome.

3. The use of any of claims 1-2, wherein the patient has a cough but does not have acute respiratory distress syndrome.

4. The use of any of claims 1-3, wherein the patient is over the age of 60 and/or has one or more other lung diseases.

5. The use of claim 4, wherein the patient has or has a history of having asthma, pneumothorax, atelectasis, bronchitis, chronic obstructive pulmonary disease, lung cancer or pneumonia.

6. The use of any of claims 1-5, wherein the patient has or is expected to develop acute kidney injury.

7. The use of any of claims 1-6, wherein the patient has or is expected to develop thrombosis.

8. The use of any of claims 1-7, wherein the patient has a prothrombotic coagulation profile but does not have thrombosis.

9. The use of claim 8, wherein the patient has increased levels of D-dimer.


10. The use of any of claims 1-9, wherein the patient is over the age of 60 and/or has one or more risk factors for developing thrombosis.

11. The use of any of claims 1-10, wherein the patient has or has had a thrombotic event.

12. The use of any of claims 1-11, wherein the medicament is to be administered systemically.


13. The use of claim 12, wherein the medicament is to be administered orally or intravenously.

14. The use of any of claims 1-13, wherein the active component is of the formula:



.

15. The use of any of claims 1-14, wherein fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof is is of the formula:




.

16. Use of fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of acute respiratory distress syndrome.

17. The use of claim 16, wherein the patient has a COVID-19 infection.

18. The method of any of claims 16-17, wherein the active component is of the formula:



.

19. Use of fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of thrombosis or acute kidney injury.